--- title: "Ironwood Pharma | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 113.04 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295097870.md" datetime: "2026-08-06T11:17:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295097870.md) - [en](https://longbridge.com/en/news/295097870.md) - [zh-HK](https://longbridge.com/zh-HK/news/295097870.md) generator: "portal-rs" --- # Ironwood Pharma | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 113.04 M Revenue: As of FY2026 Q2, the actual value is USD 113.04 M, missing the estimate of USD 114.73 M. EPS: As of FY2026 Q2, the actual value is USD 0.31. EBIT: As of FY2026 Q2, the actual value is USD 80.93 M. ### Segment Revenue - **Total Revenue** - Ironwood Pharmaceuticals, Inc.’s total revenue was $113,041 thousand in the second quarter of 2026, compared to $85,239 thousand in the second quarter of 2025. - Total revenue for the six months ended June 30, 2026, was $219,547 thousand, compared to $126,382 thousand for the six months ended June 30, 2025. - **Collaboration Revenue (LINZESS U.S.)** - Collaboration revenue related to sales of LINZESS in the U.S. was $110.0 million in the second quarter of 2026, an increase of 28% compared to $85.7 million for the second quarter of 2025. - **LINZESS U.S. Net Sales** - LINZESS U.S. net sales were $282.3 million in the second quarter of 2026, a 14% increase compared to $248.0 million in the second quarter of 2025. - Year-to-date LINZESS U.S. net sales were $555 million, representing 44% year-over-year growth. ### Operational Metrics - **Total Costs and Expenses** - Total costs and expenses were $33,734 thousand in the second quarter of 2026, compared to $39,918 thousand in the second quarter of 2025. - Total costs and expenses for the six months ended June 30, 2026, were $67,667 thousand, compared to $110,169 thousand for the six months ended June 30, 2025. - **GAAP Net Income** - GAAP net income was $51,291 thousand in the second quarter of 2026, compared to $23,599 thousand in the second quarter of 2025. - GAAP net income for the six months ended June 30, 2026, was $92,064 thousand, compared to - $13,787 thousand for the six months ended June 30, 2025. - **Adjusted EBITDA** - Adjusted EBITDA was $83,042 thousand in the second quarter of 2026, compared to $50,101 thousand in the second quarter of 2025. - Adjusted EBITDA for the six months ended June 30, 2026, was $159,713 thousand, compared to $45,359 thousand for the six months ended June 30, 2025. - **Research and Development (R&D) Expenses** - R&D expenses were $22.4 million in the second quarter of 2026, compared to $23.4 million in the second quarter of 2025. - **Selling, General and Administrative (SG&A) Expenses** - SG&A expenses were $11.3 million in the second quarter of 2026, compared to $16.8 million in the second quarter of 2025. - **Interest Expense** - Interest expense was $7.2 million in the second quarter of 2026, compared to $8.4 million in the second quarter of 2025. - **Interest and Investment Income** - Interest and investment income was $1.6 million in the second quarter of 2026, compared to $0.8 million in the second quarter of 2025. - **Income Tax Expense** - Income tax expense was $22.4 million in the second quarter of 2026, compared to $14.2 million in the second quarter of 2025. - **LINZESS Commercial Margin** - LINZESS commercial margin was 78% in the second quarter of 2026, compared to 69% in the second quarter of 2025. - **Net Profit for LINZESS U.S. Brand Collaboration** - Net profit for the LINZESS U.S. brand collaboration was $214.6 million in the second quarter of 2026, a 30% increase compared to $164.9 million in the second quarter of 2025. - **Total LINZESS Demand** - Total LINZESS demand in the second quarter of 2026 increased by 4% compared to the second quarter of 2025. ### Cash Flow - **Cash and Cash Equivalents** - Ironwood Pharmaceuticals, Inc. ended the second quarter of 2026 with $79.1 million of cash and cash equivalents, compared to $215.5 million at the end of 2025. - **Cash Generated from Operations** - Cash generated from operations was $58.3 million in the second quarter of 2026, compared to $15.1 million in the second quarter of 2025. - **Debt Repayment** - Ironwood Pharmaceuticals, Inc. repaid $200 million in aggregate principal amount of its 1.50% convertible senior notes at maturity in June 2026 using cash on hand. - **Revolving Credit Facility** - The outstanding principal balance on the revolving credit facility was $385.0 million as of June 30, 2026, with $165.0 million of remaining borrowing capacity. - **Accounts Receivable** - Accounts receivable were $112.7 million as of June 30, 2026. ### Unique Metrics - The U.S. Food and Drug Administration (FDA) approved LINZESS for pediatric patients 2 years of age and older with functional constipation (FC) in May 2026. - Ironwood Pharmaceuticals, Inc. initiated and is actively recruiting patients for STARS-2, a confirmatory Phase 3 clinical trial of apraglutide for patients with short bowel syndrome with intestinal failure (SBS-IF) dependent on parenteral support. ### Outlook / Guidance (2026) Ironwood Pharmaceuticals, Inc. has raised its full-year 2026 financial guidance. The company now expects LINZESS U.S. net sales to be between $1.15 billion and $1.20 billion, driven by improved net price and mid-single digit percentage demand growth. Total revenue guidance has been raised to $460 million to $485 million, and adjusted EBITDA guidance is now projected to be greater than $310 million. ### Related Stocks - [IRWD.US](https://longbridge.com/en/quote/IRWD.US.md) ## Related News & Research - [Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV](https://longbridge.com/en/news/296462167.md) - [Adaptive Biotechnologies (ADPT) Rebounds Sharply, Is The Stock Already Priced Fairly?](https://longbridge.com/en/news/296250822.md) - [REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group PLC](https://longbridge.com/en/news/296117308.md) - [Mayr Melnhof Karton (WBAG:MMK) Stock Grapples With A Relentless Margin Squeeze](https://longbridge.com/en/news/296565462.md) - [Edesa Biotech Stock Sinks After Fresh Capital Raise](https://longbridge.com/en/news/296475481.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**